Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech IncfiledCriticalJanssen Biotech Inc
Publication of AR121802A1publicationCriticalpatent/AR121802A1/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se describen anticuerpos anti-CD98 monoclonales y fragmentos de unión al antígeno de estos para suministrar un agente al cerebro de un sujeto que lo necesita. También se describen conjugados y construcciones de fusión que contienen el anticuerpo anti-CD98 o fragmento de unión al antígeno de este acoplado a un agente terapéutico o de diagnóstico, tal como un segundo anticuerpo y fragmento de unión al antígeno de este, para tratar o detectar un trastorno neurológico y/o suministrar un agente terapéutico o de diagnóstico a través de la barrera hematoencefálica. También se describen ácidos nucleicos que codifican los anticuerpos, conjugados y constructos de fusión y células huésped recombinantes relacionadas.Monoclonal anti-CD98 antibodies and antigen-binding fragments thereof for delivering an agent to the brain of a subject in need thereof are disclosed. Also described are conjugates and fusion constructs containing the anti-CD98 antibody or antigen-binding fragment thereof coupled to a diagnostic or therapeutic agent, such as a second antibody and antigen-binding fragment thereof, for treating or detecting a neurological disorder and/or deliver a diagnostic or therapeutic agent across the blood-brain barrier. Nucleic acids encoding the antibodies, conjugates and fusion constructs, and related recombinant host cells are also disclosed.
ARP210100937A2020-04-082021-04-08
ANTI-CD98 ANTIBODIES AND THEIR USES
AR121802A1
(en)
ANTIGEN-BINDING PROTEINS OR AN ANTIGEN-BINDING FRAGMENT THEREOF AND THEIR METHOD OF PRODUCTION, VECTOR, TRANSGENIC MICROORGANISM HOST CELL, IMMUNOCONJUGATE AND THEIR USE, PHARMACEUTICAL COMPOSITION AND MURINE HYBRIDOMA